Related Experiment Video

Updated: Jul 18, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure

P Ferrari1, R Micheletti, G Valentini

  • 1Prassis Istituto di Ricerche Sigma-Tau, Settimo Milanese, Milano, Italy. patrizia.ferrari@prassis.it

Medical Hypotheses
|November 23, 2006
PubMed

Insights

Heart failure (CHF) affects many globally. Istaroxime, a novel drug, improves heart muscle function by targeting calcium cycling, offering a new therapeutic strategy for heart failure.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Congestive heart failure (CHF) prevalence is rising globally, with poor patient prognosis.
  • Dysfunctional calcium (Ca2+) cycling is a key feature of failing heart muscle cells (myocytes).

Purpose of the Study:

  • To investigate the therapeutic potential of Istaroxime for treating heart failure.
  • To elucidate the dual mechanism of action of Istaroxime on cardiac function.

Main Methods:

  • Examined the effects of Istaroxime in normal and failing cardiac models (in vitro and in vivo).
  • Assessed Istaroxime's impact on Na(+), K(+)-ATPase activity and SERCA2a function.
  • Evaluated changes in cytoplasmic Ca(2+) levels and their effect on inotropy and lusitropy.

Main Results:

  • Istaroxime demonstrated a dual mechanism: inhibiting Na(+), K(+)-ATPase and stimulating SERCA2a.
  • This dual action increased cytoplasmic Ca(2+) and enhanced sarcoplasmic reticulum calcium reloading.
  • Observed improvements in both contraction (inotropy) and relaxation (lusitropy) in cardiac function.

Conclusions:

  • Istaroxime effectively modulates Ca(2+) cycling in cardiac myocytes.
  • The drug shows promise in improving both systolic and diastolic heart failure parameters.
  • Istaroxime represents a novel therapeutic approach for managing heart failure.

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.